Brian Koffman, MDCM, on Incremental Research Progress in Chronic Lymphocytic Leukemia
The cofounder, executive vice president, and chief medical officer, CLL Society, discussed updates in CLL research in the field in general and presented at the ASH 2023 meeting.
After Exa-Cel: Exploring the Next Wave of CRISPR Gene Editing Strategies
The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.
Around the Helix: Cell and Gene Therapy Company Updates – January 3, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Alexis Thompson, MD, MPH, on the Simultaneous Approvals of Exa-cel and Lovo-cel For SCD
The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.
Phase 3 Trial of Gene Modifier Therapy for Retinitis Pigmentosa Ready For 2024
Ocugen and the FDA have agreed on trial design aspects including end point, patient enrollment strategy, and study duration.
MDA 2024 to Focus on Patient Experience in Gene Therapy, Nonviral Vectors, and More
CGTLive spoke with Donald Wood, PhD, president and CEO of the MDA while looking ahead to its March conference.
Piers Blombery, MBBS, PhD, on Looking Deeper Into Effects of CAR T After CAR+ Lymphoma
The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.
Oncternal Therapeutics Proposes Protocol Changes Following Death of Patient Treated With CAR-T Therapy ONCT-808 in Phase 1/2 Trial
ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.
Prioritizing Cell and Gene Therapy Research for Pancreatic Cancer
ACGT is advancing cell and gene therapy research for pancreatic tumors and other types of cancer.
CGTLive's Clinical Trials to Watch in 2024
These, among many others, are some of the key clinical trials of gene, cell, and regenerative therapies that the CGTLive staff will be following throughout 2024.
CGTLive's Pillars of Progress 2023: Top FDA Approval News in Cell and Gene Therapy
Take a look at the stories that stood out as pillars of progress and success in endocrinology gene and cell therapy development in 2023.
CGTLive's 2023 Pillars of Progress: Most-Watched Expert Interviews
This year we reached out to numerous experts outside the context of the conference cycle to seek their insight on company announcements, pipeline therapies, and disease awareness days.
ACGT's Highlights From the International Oncolytic Virotherapy Conference
Take a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.
CGTLive's Pillars of Progress 2023: Most-Read Features
Take a look at our most-read features from 2023 that explored the biggest current topics and concerns with gene and cell therapy development across treatment fields.
CGTLive's 2023 Pillars of Progress: Most-Read Conference Coverage Stories
Take a look at the stories that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.
CGTLive's 2023 Pillars of Progress: Most-Watched Conference Interviews
Take a look at the interviews that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.
Around the Helix: Cell and Gene Therapy Company Updates – December 27, 2023
CGTLive's Pillars of Progress 2023: Top News in Cardiology
Take a look at the stories that stood out as pillars of progress and success in cardiology gene and cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Ophthalmology
Take a look at the stories that stood out as pillars of progress and success in ophthalmology cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Lysosomal Disorders
Take a look at the stories that stood out as pillars of progress and success in lysosomal storage disease gene and cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Neurology
Take a look at the stories that stood out as pillars of progress and success in neurology gene and cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Dermatology
Take a look at the stories that stood out as pillars of progress and success in dermatology gene and cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Endocrinology
CGTLive's Pillars of Progress 2023: Top News in Oncology
Take a look at the stories that stood out as pillars of progress and success in oncology cell therapy development in 2023.
CGTLive's Pillars of Progress 2023: Top News in Hematology
Take a look at the stories that stood out as pillars of progress and success in hematology gene and cell therapy development in 2023.
CGTLive’s Weekly Rewind – December 22, 2023
Review top news and interview highlights from the week ending December 22, 2023.
Some Dose-Dependent Neurological Benefits Seen With AMT-130 Huntington Disease Gene Therapy
uniQure plans to initiate regulatory discussions in the US and Europe in the first quarter of 2024.
BrainStorm Cell Therapeutics Seeks Special Protocol Assessment for New NurOwn Trial After Meeting With FDA
The company characterized the meeting as “productive”.
Mazyar Shadman, MD, on Evaluating MB-106 in a Multicenter Study
The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.
Around the Helix: Cell and Gene Therapy Company Updates – December 20, 2023